Orforglipron vs Semaglutide

Eli Lilly's oral, non-peptide GLP-1 receptor agonist. The first viable once-daily pill competing with injectable semaglutide and tirzepatide. Expected FDA approval in 2026–2027.

A GLP-1 receptor agonist originally approved for type 2 diabetes and now widely used for chronic weight management, producing 15%+ reductions in body weight over 12 months in clinical trials.

Orforglipron is a small molecule (not a peptide) that mimics GLP-1 binding. Its oral bioavailability is the breakthrough — no injection, no cold-chain storage, no complex dosing schedule.

Semaglutide mimics the incretin hormone GLP-1, slowing gastric emptying, reducing appetite via hypothalamic signalling, and enhancing glucose-dependent insulin secretion. The result is sustained calorie reduction without conscious restriction.

12–36 mg oral once daily (in trials)

0.25 mg weekly, titrated up to 2.4 mg weekly for weight loss

~25 hours

~7 days

Oral

Subcutaneous once weekly, Oral (lower bioavailability)

investigational

approved

Not yet listed

Not yet listed